Ondameton (Ondansetron)

Ondansetron, the active ingredient in Ondameton, is a 5-HT3 receptor antagonist presented as a 4 mg tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy and surgery in adult and paediatric patients. GNH USA supplies Ondameton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondameton is a selective 5‑HT3 receptor antagonist used in the management of several nausea‑vomiting pathways. - Chemotherapy‑induced nausea and vomiting (CINV): helps prevent and control acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting (RINV): reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting (PONV): decreases incidence of nausea after surgical procedures.

Adverse reactions to ondansetron are generally mild to moderate and vary with the route and dose.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: loose stools reported in some patients. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with IV administration. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Neuroleptic malignant‑like reactions: extremely rare but potentially life‑threatening.

When prescribing Ondameton, clinicians should consider several safety aspects. - Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use. - Concomitant serotonergic drugs: evaluate for serotonin syndrome risk. - Pregnancy: use only if clearly needed; weigh maternal benefit against potential fetal risk. - Breastfeeding: monitor infant for possible sedation or gastrointestinal effects. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ondameton may interact with other medicines that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., haloperidol, droperdroge). - Macrolide antibiotics (e.g., erythromycin, clarithromycin): may elevate plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, fluconazole). - CYP2D6 substrates (such as codeine) that may have altered metabolism. - Serotonergic agents (e.g., tramadol, duloxetine). - Diuretics that affect electrolyte status. - Other anti‑emetics (e.g., dexamethasone) used in combination protocols.